[1] Dartois VA,Rubin EJ.Anti-tuberculosis treatment strategies and drug development:challenges and priorities. Nat Rev Microbiol,2022,20(11):685-701. doi:10.1038/s41579-022-00731-y. [2] Liu YH,Guo Y,Xu H,et al.Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. Infect Drug Resist,2021,14:3667-3671. doi:10.2147/IDR.S326386. [3] Huang CK,Huang JY,Chang CH,et al.The effect of statins on the risk of anti-tuberculosis drug-induced liver injury among patients with active tuberculosis:A cohort study.J Microbiol Immunol Infect,2024,S1684-1182(24)00069-0. doi:10.1016/j.jmii.2024.04.002. [4] Zhao H,Wang Y,Zhang T,et al.Drug-Induced Liver Injury from Anti-Tuberculosis Treatment:A Retrospective Cohort Study.Med Sci Monit,2020,26:e920350. doi:10.12659/MSM.920350. [5] Zhong T,Fan Y,Dong XL,et al.An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis.Front Pharmacol,2021,12:708522. doi:10.3389/fphar.2021.708522. [6] Wang D,Cai XL,Lin X,et al.Hepatoprotective drugs for prevention of liver injury resulting from anti-tuberculosis treatment:A meta-analysis of cohort studies.Infect Med (Beijing),2022,1(3):154-162. doi:10.1016/j.imj.2022.07.003. [7] 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09. [8] Mao Y,Ma S,Liu C,et al.Technology Committee on DILI Prevention,Management,Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease,Chinese Society of Hepatology,Chinese Medical Association. Chinese guideline for the diagnosis and treatment of drug-induced liver injury:an update.Hepatol Int,2024,18(2):384-419. doi:10.1007/s12072-023-10633-7. [9] Danan G,Teschke R.RUCAM in Drug and Herb Induced Liver Injury:The Update. Int J Mol Sci,2015,17(1):14. doi:10.3390/ijms17010014. [10] Jiang F,Yan H,Liang L,et al.Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI):Large cohort study involving 4652 Chinese adult tuberculosis patients.Liver Int,2021,41(7):1565-1575. doi:10.1111/liv.14896. [11] Lucena MI,Sanabria J,García-Cortes M,et al.Drug-induced liver injury in older people.Lancet Gastroenterol Hepatol,2020,5(9):862-874. doi:10.1016/S2468-1253(20)30006-6. [12] Ho CM,Chen CL,Chang CH,et al.Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment.Biomedicines,2021,9(8):891. doi:10.3390/biomedicines9080891. [13] D Freire I,L Fielding K,A J Moore D. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?.PLoS One,2023,18(5):e0286306. doi:10.1371/journal.pone.0286306. [14] Bright-Thomas RJ,Gondker AR,Morris J,et al.Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period.Int J Tuberc Lung Dis,2016,20(12):1621-1624. doi:10.5588/ijtld.16.0370. [15] Devarbhavi H,Aithal G,Treeprasertsuk S,et al.Asia Pacific Association of Study of Liver. Drug-induced liver injury:Asia Pacific Association of Study of Liver consensus guidelines.Hepatol Int,2021,15(2):258-282. doi:10.1007/s12072-021-10144-3. [16] Cavaco MJ,Alcobia C,Oliveiros B,et al.Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment-A Study from Patients of Portuguese Health Centers.J Pers Med,2022,12(5):790. doi:10.3390/jpm12050790. [17] Gualano G,Zace D,Mosti S,et al.Utility of Liver Biopsy in the Diagnosis and Management of Possible Drug-Induced Liver Injury in Patients Receiving Antituberculosis Therapy:A Retrospective Study.Infect Dis Rep,2023,15(6):735-746. doi:10.3390/idr15060066. [18] 张洋婷,卢学昭,李晓娜,等.肺结核合并糖尿病患者药物性肝损伤影响因素分析.中国防痨杂志,2022,44(1):64-70. [19] Chou C,Veracruz N,Chitnis AS,et al.Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection:A systematic review and meta-analysis.J Viral Hepat,2022,29(12):1107-1114. doi:10.1111/jvh.13751. [20] Lui GCY,Wong NS,Wong RYK,et al.Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection.Clin Infect Dis,2020,70(4):660-666. doi:10.1093/cid/ciz241. [21] Han Y,Xia S,Zhou J. Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs.Pak J Pharm Sci,2018,31(4(Special)):1667-1670. [22] 陈木兴,吴迪,林友飞,等.抗结核药物引发肝损伤的影响因素研究进展.抗感染药学,2023,20(10):1046-1050. [23] Lim J,Kim JS,Kim HW,et al.Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment:A Multicenter Prospective Observational Cohort Study in Korea.Open Forum Infect Dis,2023,10(8):ofad422. doi:10.1093/ofid/ofad422. [24] Chen M,Suzuki A,Borlak J,et al.Drug-induced liver injury:Interactions between drug properties and host factors.J Hepatol,2015,63(2):503-14. doi:10.1016/j.jhep.2015.04.016. |